139 related articles for article (PubMed ID: 19655144)
21. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study.
Ravaud A; de la Fouchardière C; Caron P; Doussau A; Do Cao C; Asselineau J; Rodien P; Pouessel D; Nicolli-Sire P; Klein M; Bournaud-Salinas C; Wemeau JL; Gimbert A; Picat MQ; Pedenon D; Digue L; Daste A; Catargi B; Delord JP
Eur J Cancer; 2017 May; 76():110-117. PubMed ID: 28301826
[TBL] [Abstract][Full Text] [Related]
22. Sunitinib in urothelial cancer: clinical, pharmacokinetic, and immunohistochemical study of predictors of response.
Gallagher DJ; Al-Ahmadie H; Ostrovnaya I; Gerst SR; Regazzi A; Garcia-Grossman I; Riches J; Gounder SK; Flaherty AM; Trout A; Milowsky MI; Bajorin DF
Eur Urol; 2011 Aug; 60(2):344-9. PubMed ID: 21645967
[TBL] [Abstract][Full Text] [Related]
23. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
24. Experience in the use of sunitinib given as a single agent in metastatic chemoresistant and castration-resistant prostate cancer patients.
Castellano D; González-Larriba JL; Antón-Aparicio LM; Cassinello J; Grande E; Esteban E; Sepúlveda J
Expert Opin Pharmacother; 2011 Nov; 12(16):2433-9. PubMed ID: 21671835
[TBL] [Abstract][Full Text] [Related]
25. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
26. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
[TBL] [Abstract][Full Text] [Related]
27. Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck.
Hussain M; Gadgeel S; Kucuk O; Du W; Salwen W; Ensley J
Cancer; 1999 Dec; 86(11):2364-9. PubMed ID: 10590379
[TBL] [Abstract][Full Text] [Related]
28. Multicenter, phase II trial of sunitinib in previously treated, advanced non-small-cell lung cancer.
Socinski MA; Novello S; Brahmer JR; Rosell R; Sanchez JM; Belani CP; Govindan R; Atkins JN; Gillenwater HH; Pallares C; Tye L; Selaru P; Chao RC; Scagliotti GV
J Clin Oncol; 2008 Feb; 26(4):650-6. PubMed ID: 18235126
[TBL] [Abstract][Full Text] [Related]
29. A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly targeted agents in ACC.
Chau NG; Hotte SJ; Chen EX; Chin SF; Turner S; Wang L; Siu LL
Ann Oncol; 2012 Jun; 23(6):1562-70. PubMed ID: 22080184
[TBL] [Abstract][Full Text] [Related]
30. Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma.
Elser C; Siu LL; Winquist E; Agulnik M; Pond GR; Chin SF; Francis P; Cheiken R; Elting J; McNabola A; Wilkie D; Petrenciuc O; Chen EX
J Clin Oncol; 2007 Aug; 25(24):3766-73. PubMed ID: 17704426
[TBL] [Abstract][Full Text] [Related]
31. Role of the lean body mass and of pharmacogenetic variants on the pharmacokinetics and pharmacodynamics of sunitinib in cancer patients.
Narjoz C; Cessot A; Thomas-Schoemann A; Golmard JL; Huillard O; Boudou-Rouquette P; Behouche A; Taieb F; Durand JP; Dauphin A; Coriat R; Vidal M; Tod M; Alexandre J; Loriot MA; Goldwasser F; Blanchet B
Invest New Drugs; 2015 Feb; 33(1):257-68. PubMed ID: 25344452
[TBL] [Abstract][Full Text] [Related]
32. A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07).
Hutterer M; Nowosielski M; Haybaeck J; Embacher S; Stockhammer F; Gotwald T; Holzner B; Capper D; Preusser M; Marosi C; Oberndorfer S; Moik M; Buchroithner J; Seiz M; Tuettenberg J; Herrlinger U; Wick A; Vajkoczy P; Stockhammer G
Neuro Oncol; 2014 Jan; 16(1):92-102. PubMed ID: 24311637
[TBL] [Abstract][Full Text] [Related]
33. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study.
Hensley ML; Sill MW; Scribner DR; Brown J; Debernardo RL; Hartenbach EM; McCourt CK; Bosscher JR; Gehrig PA
Gynecol Oncol; 2009 Dec; 115(3):460-5. PubMed ID: 19811811
[TBL] [Abstract][Full Text] [Related]
34. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate.
Liu G; Jeraj R; Vanderhoek M; Perlman S; Kolesar J; Harrison M; Simoncic U; Eickhoff J; Carmichael L; Chao B; Marnocha R; Ivy P; Wilding G
Clin Cancer Res; 2011 Dec; 17(24):7634-44. PubMed ID: 22038997
[TBL] [Abstract][Full Text] [Related]
35. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumors: a children's oncology group study.
Dubois SG; Shusterman S; Ingle AM; Ahern CH; Reid JM; Wu B; Baruchel S; Glade-Bender J; Ivy P; Grier HE; Adamson PC; Blaney SM
Clin Cancer Res; 2011 Aug; 17(15):5113-22. PubMed ID: 21690570
[TBL] [Abstract][Full Text] [Related]
36. A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: An NRG Oncology/Gynecologic Oncology Group Study (GOG-254).
Chan JK; Brady W; Monk BJ; Brown J; Shahin MS; Rose PG; Kim JH; Secord AA; Walker JL; Gershenson DM
Gynecol Oncol; 2018 Aug; 150(2):247-252. PubMed ID: 29921512
[TBL] [Abstract][Full Text] [Related]
37. Phase II trial of single-agent foretinib (GSK1363089) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck.
Seiwert T; Sarantopoulos J; Kallender H; McCallum S; Keer HN; Blumenschein G
Invest New Drugs; 2013 Apr; 31(2):417-24. PubMed ID: 22918720
[TBL] [Abstract][Full Text] [Related]
38. A phase 1b trial of the combination of the antiangiogenic agent sunitinib and radiation therapy for patients with primary and metastatic central nervous system malignancies.
Wuthrick EJ; Kamrava M; Curran WJ; Werner-Wasik M; Camphausen KA; Hyslop T; Axelrod R; Andrews DW; Glass J; Machtay M; Dicker AP
Cancer; 2011 Dec; 117(24):5548-59. PubMed ID: 21647871
[TBL] [Abstract][Full Text] [Related]
39. Risk of hematologic toxicities in cancer patients treated with sunitinib: a systematic review and meta-analysis.
Funakoshi T; Latif A; Galsky MD
Cancer Treat Rev; 2013 Nov; 39(7):818-30. PubMed ID: 23455076
[TBL] [Abstract][Full Text] [Related]
40. A routine feasible HPLC analysis for the anti-angiogenic tyrosine kinase inhibitor, sunitinib, and its main metabolite, SU12662, in plasma.
Etienne-Grimaldi MC; Renée N; Izzedine H; Milano G
J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Nov; 877(29):3757-61. PubMed ID: 19797000
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]